MET and prostate cancer: The tyrosine kinase c-Met, also called MET and hepatocyte growth factor receptor (HGFR), is a key regulator of organ development and cancer progression and has been studied in many cancer types such as lung cancer, gastric cancer, prostate cancer and so on [4–7].